[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:pgr-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"PGR Gene",22,20,[8,16,23,30,36,42,48,54,61,67,73,79,85,91,97,103,109,115,121,127,133,140],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07205822","A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer",[12],"Phase 3","RECRUITING","2026-08-26T02:16:16.169331Z","2026-07-30T01:46:14.435695Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07137871","Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4\u002F6 Inhibitor and Hormonal Therapy",[20],"Phase 1","2026-08-26T02:16:46.147215Z","2026-05-05T02:43:29.529779Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05524584","Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer",[27],"Phase 2","2026-08-26T02:18:02.701182Z","2026-05-05T02:43:28.875805Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06518837","Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive\u002FHER2 Negative Breast Cancer",[27],"2026-08-26T02:15:24.145250Z","2026-05-05T02:43:28.807707Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT02945579","Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy",[],"2026-08-26T02:17:56.243868Z","2026-05-05T02:43:28.564466Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05827081","Phase IIIb Study of Ribociclib + ET in Early Breast Cancer",[12],"2026-08-26T02:16:51.982021Z","2026-05-05T02:43:28.508321Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06072612","Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.",[12],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:28.478069Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT06926868","A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)",[58],"Phase 2\u002FPhase 3","2026-08-26T02:16:57.705506Z","2026-05-05T02:43:28.347122Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT04852887","De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)",[12],"2026-08-26T02:17:33.807405Z","2026-05-05T02:43:27.943379Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07069595","PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease",[27],"2026-08-26T02:15:37.042762Z","2026-05-05T02:43:26.906414Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07218432","A Study of the TheraBionic P1 Device in Breast Cancer",[],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:26.769244Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04521764","A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer",[20],"2026-08-26T02:16:54.044282Z","2026-05-05T02:35:31.754606Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06324240","Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer",[20],"2026-08-26T02:15:28.524219Z","2026-05-05T02:35:31.741776Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06067503","Biomarkers to Detect Endocrine Therapy Resistance",[27],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:28.873057Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07211178","Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies",[],"2026-08-26T02:17:36.611194Z","2026-05-13T02:55:06.672947Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT02302742","Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry",[],"2026-08-26T02:17:28.381459Z","2026-05-13T02:55:06.091980Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06123988","Prolonged Overnight Fasting and\u002For Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer",[],"2026-08-26T02:18:35.425468Z","2026-05-05T02:43:29.356630Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT07206121","Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery",[],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.812664Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06344416","Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform",[],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:28.362332Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT05736367","Investigating the Metabolic Pathways in Hormone Receptor Positive\u002FHER2 Negative Breast Cancer",[],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:28.291777Z",{"nct_id":134,"title":135,"phases":136,"status":137,"updated_at":138,"content_modified":139},"NCT06154590","Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor",[],"NOT_YET_RECRUITING","2026-08-26T02:18:12.612955Z","2026-05-13T02:55:06.420796Z",{"nct_id":141,"title":142,"phases":143,"status":137,"updated_at":144,"content_modified":145},"NCT07553234","Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment",[],"2026-08-26T02:15:56.561131Z","2026-05-05T02:43:27.252356Z"]